301
|
Liu J, Zhu M, Xia X, Huang Y, Zhang Q, Wang X. Jumonji domain-containing protein 1A promotes cell growth and progression via transactivation of c-Myc expression and predicts a poor prognosis in cervical cancer. Oncotarget 2018; 7:85151-85162. [PMID: 27835890 PMCID: PMC5356725 DOI: 10.18632/oncotarget.13208] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2016] [Accepted: 10/26/2016] [Indexed: 02/07/2023] Open
Abstract
Jumonji domain-containing protein 1A (JMJD1A) plays a key role in the development and progression of several cancers. Here, we showed that the expression of JMJD1A is increased in cervical cancer cells and tissues, and that suppression of JMJD1A inhibits proliferation, migration, and invasion of cervical cancer cells. JMJD1A induced transcription of c-Myc, which is essential for cervical cancer growth and progression. Clinical data showed that JMJD1A expression correlated with lymph node metastasis (P=0.031) and FIGO stage (P=0.007). Increased c-Myc levels were associated with tumor differentiation (P=0.007) and FIGO stage (P<0.001). JMJD1A protein levels correlated with c-Myc expression (P<0.001), and high co-expression of the two proteins correlated with a poor prognosis. Survival analysis showed that JMJD1A and c-Myc levels are independent prognostic factors for cervical cancer patients. These results suggest that JMJD1A is a promising therapeutic target in cervical cancer.
Collapse
Affiliation(s)
- Jue Liu
- Department of Obstetrics and Gynecology, The Second Affiliated Hospital of University of South China, Hengyang, Hunan Province, 421001, P.R. China
| | - Ming Zhu
- Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, P.R. China
| | - Xue Xia
- Department of Orthopaedics, The Second Affiliated Hospital of University of South China, Hengyang, Hunan Province, 421001, P.R. China
| | - Yuliang Huang
- Department of Obstetrics and Gynecology, The Second Affiliated Hospital of University of South China, Hengyang, Hunan Province, 421001, P.R. China
| | - Qunfeng Zhang
- Department of Obstetrics and Gynecology, The Second Affiliated Hospital of University of South China, Hengyang, Hunan Province, 421001, P.R. China
| | - Xiaoxu Wang
- Department of Orthopaedics, The Second Affiliated Hospital of University of South China, Hengyang, Hunan Province, 421001, P.R. China
| |
Collapse
|
302
|
Selection and identification of novel peptides specifically targeting human cervical cancer. Amino Acids 2018; 50:577-592. [DOI: 10.1007/s00726-018-2539-1] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2017] [Accepted: 01/18/2018] [Indexed: 12/30/2022]
|
303
|
He L, Yang H, Zhou S, Zhu H, Mao H, Ma Z, Wu T, Kumar AK, Kathera C, Janardhan A, Pan F, Hu Z, Yang Y, Luo L, Guo Z. Synergistic antitumor effect of combined paclitaxel with FEN1 inhibitor in cervical cancer cells. DNA Repair (Amst) 2018; 63:1-9. [PMID: 29358095 DOI: 10.1016/j.dnarep.2018.01.003] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2017] [Revised: 01/06/2018] [Accepted: 01/08/2018] [Indexed: 12/22/2022]
Abstract
Studies on cervical cancer are urgently required to improve clinical outcomes. As a major anticancer drug for cervical cancer, paclitaxel has been used for many years in clinical therapy but its therapeutic efficacy is limited by common obstacle from cancer cells. The enhanced DNA repair pathways of cancer cells have been proved to survive DNA damage induced by chemotherapeutic drug. Inhibitors of specific DNA repair pathway can sensitize cancer cells to the treatment of chemotherapeutic drugs. In this paper we found that the effect of paclitaxel can be significantly improved when used in combination with FEN1 inhibitor SC13, suggesting a synergistic mechanism between the two compounds. Our studies suggest that FEN1 inhibition could be a novel strategy of tumor-targeting therapy for cervical cancer. Our work also revealed that paclitaxel demonstrates stronger synergistic effect with SC13 than other common used chemical drugs such as doxorubicin, carboplatin or camptothecin on cervical cancer cells.
Collapse
Affiliation(s)
- Lingfeng He
- Changzhou No. 7 People's Hospital, China; Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, 1 WenYuan Road, Nanjing, 210023, China
| | - Huan Yang
- Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, 1 WenYuan Road, Nanjing, 210023, China
| | - Shiying Zhou
- Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, 1 WenYuan Road, Nanjing, 210023, China
| | - Hong Zhu
- Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, 1 WenYuan Road, Nanjing, 210023, China
| | - Huiwen Mao
- Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, 1 WenYuan Road, Nanjing, 210023, China
| | - Zhuang Ma
- Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, 1 WenYuan Road, Nanjing, 210023, China
| | - Ting Wu
- Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, 1 WenYuan Road, Nanjing, 210023, China
| | - Alagamuthu Karthick Kumar
- Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, 1 WenYuan Road, Nanjing, 210023, China
| | - Chandrasekhar Kathera
- Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, 1 WenYuan Road, Nanjing, 210023, China
| | - Avilala Janardhan
- Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, 1 WenYuan Road, Nanjing, 210023, China
| | - Feiyan Pan
- Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, 1 WenYuan Road, Nanjing, 210023, China
| | - Zhigang Hu
- Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, 1 WenYuan Road, Nanjing, 210023, China
| | | | - Libo Luo
- Changzhou No. 7 People's Hospital, China.
| | - Zhigang Guo
- Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, 1 WenYuan Road, Nanjing, 210023, China.
| |
Collapse
|
304
|
Gee MS, Atri M, Bandos AI, Mannel RS, Gold MA, Lee SI. Identification of Distant Metastatic Disease in Uterine Cervical and Endometrial Cancers with FDG PET/CT: Analysis from the ACRIN 6671/GOG 0233 Multicenter Trial. Radiology 2017; 287:176-184. [PMID: 29185901 DOI: 10.1148/radiol.2017170963] [Citation(s) in RCA: 63] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Purpose To assess the accuracy of staging positron emission tomography (PET)/computed tomography (CT) in detecting distant metastasis in patients with local-regionally advanced cervical and high-risk endometrial cancer in the clinical trial by the American College of Radiology Imaging Network (ACRIN) and the Gynecology Oncology Group (GOG) (ACRIN 6671/GOG 0233) and to compare central and institutional reader performance. Materials and Methods In this prospective multicenter trial, PET/CT and clinical data were reviewed for patients enrolled in ACRIN 6671/GOG 0233. Two central readers, blinded to site read and reference standard, reviewed PET/CT images for distant metastasis. Central review was then compared with institutional point-of-care interpretation. Reference standard was pathologic and imaging follow-up. Test performance for central and site reviews of PET/CT images was calculated and receiver operating characteristic analysis was performed. Generalized estimating equations and nonparametric bootstrap procedure for clustered data were used to assess statistical significance. Results There were 153 patients with cervical cancer and 203 patients with endometrial cancer enrolled at 28 sites. Overall prevalence of distant metastasis was 13.7% (21 of 153) for cervical cancer and 11.8% (24 of 203) for endometrial cancer. Central reader PET/CT interpretation demonstrated sensitivity, specificity, positive predictive value (PPV), and negative predictive value of 54.8%, 97.7%, 79.3%, and 93.1% for cervical cancer metastasis versus 64.6%, 98.6%, 86.1%, and 95.4% for endometrial cancer, respectively. By comparison, local institutional review demonstrated sensitivity, specificity, PPV, and negative predictive value of 47.6%, 93.9%, 55.6%, and 91.9% for cervical cancer metastasis and 66.7%, 93.9%, 59.3%, and 95.5% for endometrial cancer, respectively. For central readers, the specificity and PPV of PET/CT detection of cervical and endometrial cancer metastases were all significantly higher compared with that of local institutional review (P < .05). Central reader area under the receiver operating characteristic curve (AUC) values were 0.78 and 0.89 for cervical and endometrial cancer, respectively; these were not significantly different from local institutional AUC values (0.75 and 0.84, respectively; P > .05 for both). Conclusion FDG PET/CT demonstrates high specificity and PPV for detecting distant metastasis in cervical and endometrial cancer and should be included in the staging evaluation. Blinded central review of imaging provides improved specificity and PPV for the detection of metastases and should be considered for future oncologic imaging clinical trials. © RSNA, 2017.
Collapse
Affiliation(s)
- Michael S Gee
- From the Department of Radiology, Massachusetts General Hospital, 55 Fruit St, Ellison 237, Boston, Mass 02114 (M.S.G., S.I.L.); Department of Medical Imaging, University of Toronto, Toronto, Canada (M.A.); Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pa (A.I.B.); Department of Obstetrics and Gynecology, University of Oklahoma Health Science Center, Oklahoma City, Okla (R.S.M.); and Department of Obstetrics and Gynecology, Tulsa Cancer Institute, Tulsa, Okla (M.A.G.)
| | - Mostafa Atri
- From the Department of Radiology, Massachusetts General Hospital, 55 Fruit St, Ellison 237, Boston, Mass 02114 (M.S.G., S.I.L.); Department of Medical Imaging, University of Toronto, Toronto, Canada (M.A.); Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pa (A.I.B.); Department of Obstetrics and Gynecology, University of Oklahoma Health Science Center, Oklahoma City, Okla (R.S.M.); and Department of Obstetrics and Gynecology, Tulsa Cancer Institute, Tulsa, Okla (M.A.G.)
| | - Andriy I Bandos
- From the Department of Radiology, Massachusetts General Hospital, 55 Fruit St, Ellison 237, Boston, Mass 02114 (M.S.G., S.I.L.); Department of Medical Imaging, University of Toronto, Toronto, Canada (M.A.); Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pa (A.I.B.); Department of Obstetrics and Gynecology, University of Oklahoma Health Science Center, Oklahoma City, Okla (R.S.M.); and Department of Obstetrics and Gynecology, Tulsa Cancer Institute, Tulsa, Okla (M.A.G.)
| | - Robert S Mannel
- From the Department of Radiology, Massachusetts General Hospital, 55 Fruit St, Ellison 237, Boston, Mass 02114 (M.S.G., S.I.L.); Department of Medical Imaging, University of Toronto, Toronto, Canada (M.A.); Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pa (A.I.B.); Department of Obstetrics and Gynecology, University of Oklahoma Health Science Center, Oklahoma City, Okla (R.S.M.); and Department of Obstetrics and Gynecology, Tulsa Cancer Institute, Tulsa, Okla (M.A.G.)
| | - Michael A Gold
- From the Department of Radiology, Massachusetts General Hospital, 55 Fruit St, Ellison 237, Boston, Mass 02114 (M.S.G., S.I.L.); Department of Medical Imaging, University of Toronto, Toronto, Canada (M.A.); Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pa (A.I.B.); Department of Obstetrics and Gynecology, University of Oklahoma Health Science Center, Oklahoma City, Okla (R.S.M.); and Department of Obstetrics and Gynecology, Tulsa Cancer Institute, Tulsa, Okla (M.A.G.)
| | - Susanna I Lee
- From the Department of Radiology, Massachusetts General Hospital, 55 Fruit St, Ellison 237, Boston, Mass 02114 (M.S.G., S.I.L.); Department of Medical Imaging, University of Toronto, Toronto, Canada (M.A.); Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pa (A.I.B.); Department of Obstetrics and Gynecology, University of Oklahoma Health Science Center, Oklahoma City, Okla (R.S.M.); and Department of Obstetrics and Gynecology, Tulsa Cancer Institute, Tulsa, Okla (M.A.G.)
| |
Collapse
|
305
|
Goto M, Osada S, Imagawa M, Nishizuka M. FAD104, a regulator of adipogenesis, is a novel suppressor of TGF-β-mediated EMT in cervical cancer cells. Sci Rep 2017; 7:16365. [PMID: 29180690 PMCID: PMC5703855 DOI: 10.1038/s41598-017-16555-3] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2017] [Accepted: 11/15/2017] [Indexed: 01/05/2023] Open
Abstract
Epithelial-to-mesenchymal transition (EMT) is a biological process in which epithelial cells translate into a mesenchymal phenotype with invasive capacities, contributing to tumour progression, metastasis, and the acquisition of chemotherapy resistance. To identify new therapeutic targets for cancers, it is important to clarify the molecular mechanism of induction of EMT. We have previously reported that fad104, a positive regulator of adipocyte differentiation, suppressed the invasion and metastasis of melanoma and breast cancer cells. In this study, we showed that FAD104 functions as a novel suppressor of transforming growth factor-β (TGF-β)–mediated EMT in cervical cancer cells. Expression of FAD104 is upregulated during TGF-β–mediated EMT in human cervical cancer HeLa cells. Reduction of fad104 expression enhanced TGF-β–mediated EMT and migration in HeLa cells. Conversely, overexpression of FAD104 suppressed TGF-β–induced EMT. In addition, we showed that FAD104 negatively regulated phosphorylation of Smad2 and Smad3 but positively regulated phosphorylation of Smad1/5/8 via treatment with TGF-β. These findings demonstrate that FAD104 is a novel suppressor of TGF-β signalling and represses TGF-β–mediated EMT in cervical cancer cells.
Collapse
Affiliation(s)
- Motoharu Goto
- Department of Molecular Biology, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, Aichi, 467-8603, Japan
| | - Shigehiro Osada
- Department of Molecular Biology, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, Aichi, 467-8603, Japan
| | - Masayoshi Imagawa
- Department of Molecular Biology, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, Aichi, 467-8603, Japan
| | - Makoto Nishizuka
- Department of Molecular Biology, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, Aichi, 467-8603, Japan.
| |
Collapse
|
306
|
Chellappan DK, Chellian J, Ng ZY, Sim YJ, Theng CW, Ling J, Wong M, Foo JH, Yang GJ, Hang LY, Nathan S, Singh Y, Gupta G. The role of pazopanib on tumour angiogenesis and in the management of cancers: A review. Biomed Pharmacother 2017; 96:768-781. [PMID: 29054093 DOI: 10.1016/j.biopha.2017.10.058] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2017] [Revised: 10/05/2017] [Accepted: 10/10/2017] [Indexed: 01/03/2023] Open
Abstract
Pazopanib is a relatively new compound to be introduced into the chemotherapy field. It is thought to have decent anti-angiogenic properties, which gives an additional hope for the treatment of certain types of cancers. A systematic review solely discussing about pazopanib and its anti-angiogenic effect is yet to be published to date, despite several relevant clinical trials being conducted over the recent years. In this review, we aim to investigate the mechanism of pazopanib's anti-angiogenic effect and its effectiveness in treating several cancers. We have included, in this study, findings from electronically searchable data from randomized clinical trials, clinical studies, cohort studies and other relevant articles. A total of 352 studies were included in this review. From the studies, the effect of pazopanib in various cancers or models was observed and recorded. Study quality is indefinite, with a few decent quality articles. The most elaborately studied cancers include renal cell carcinoma, solid tumors, advanced solid tumors, soft tissue sarcoma, breast cancer and gynecological cancers. In addition, several less commonly studied cancers are included in the studies as well. Pazopanib had demonstrated its anti-angiogenic effect based on favorable results observed in cancers, which are caused by angiogenesis-related mechanisms, such as renal cell carcinoma, solid tumors, advanced solid tumors and soft tissue sarcoma. This review was conducted to study, analyze and review the anti-angiogenic properties of pazopanib in various cancers. The results obtained can provide a decent reference when considering treatment options for angiogenesis-related malignancies. Furthermore, the definite observations of the anti-angiogenic effects of pazopanib could provide newer insights leading to the future development of drugs of the same mechanism with increased efficiency and reduced adverse effects.
Collapse
Affiliation(s)
- Dinesh Kumar Chellappan
- Department of Life Sciences, School of Pharmacy, International Medical University, Kuala Lumpur, 57000, Malaysia
| | - Jestin Chellian
- Department of Life Sciences, School of Pharmacy, International Medical University, Kuala Lumpur, 57000, Malaysia
| | - Zhao Yin Ng
- Department of Life Sciences, School of Pharmacy, International Medical University, Kuala Lumpur, 57000, Malaysia; School of Pharmaceutical Sciences, Jaipur National University, Jagatpura, Jaipur, 302017, India
| | - Yan Jinn Sim
- Department of Life Sciences, School of Pharmacy, International Medical University, Kuala Lumpur, 57000, Malaysia
| | - Chiu Wei Theng
- Department of Life Sciences, School of Pharmacy, International Medical University, Kuala Lumpur, 57000, Malaysia
| | - Joyce Ling
- Department of Life Sciences, School of Pharmacy, International Medical University, Kuala Lumpur, 57000, Malaysia
| | - Mei Wong
- Department of Life Sciences, School of Pharmacy, International Medical University, Kuala Lumpur, 57000, Malaysia
| | - Jia Hui Foo
- Department of Life Sciences, School of Pharmacy, International Medical University, Kuala Lumpur, 57000, Malaysia
| | - Goh Jun Yang
- Department of Life Sciences, School of Pharmacy, International Medical University, Kuala Lumpur, 57000, Malaysia
| | - Li Yu Hang
- Department of Life Sciences, School of Pharmacy, International Medical University, Kuala Lumpur, 57000, Malaysia
| | - Saranyah Nathan
- Department of Life Sciences, School of Pharmacy, International Medical University, Kuala Lumpur, 57000, Malaysia
| | - Yogendra Singh
- School of Pharmaceutical Sciences, Jaipur National University, Jagatpura, Jaipur, 302017, India
| | - Gaurav Gupta
- School of Pharmaceutical Sciences, Jaipur National University, Jagatpura, Jaipur, 302017, India.
| |
Collapse
|
307
|
Fetcko K, Gondim DD, Bonnin JM, Dey M. Cervical cancer metastasis to the brain: A case report and review of literature. Surg Neurol Int 2017; 8:181. [PMID: 28868193 PMCID: PMC5569407 DOI: 10.4103/sni.sni_111_17] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2017] [Accepted: 05/30/2017] [Indexed: 01/08/2023] Open
Abstract
Background: Intracranial metastasis from cervical cancer is a rare occurrence. Methods: In this study we describe a case of cervical cancer metastasis to the brain and perform an extensive review of literature from 1956 to 2016, to characterize clearly the clinical presentation, treatment options, molecular markers, targeted therapies, and survival of patients with this condition. Results: An elderly woman with history of cervical cancer in remission, presented 2 years later with a right temporo-parietal tumor, which was treated with surgery and subsequent stereotactic radiosurgery (SRS) to the resection cavity. She then returned 5 months later with a second solitary right lesion; she again underwent surgery and SRS to the resection cavity with no signs of recurrence 6 months later. According to the reviewed literature, the most common clinical presentation included females with median age of 48 years; presenting symptoms such as headache, weakness/hemiplegia/hemiparesis, seizure, and altered mental status (AMS)/confusion; multiple lesions mostly supratentorially located; poorly differentiated squamous cell carcinoma; and additional recurrences at other sites. The best approach to treatment is a multimodal plan, consisting of SRS or whole brain radiation therapy (WBRT) for solitary brain metastases followed by chemotherapy for systemic disease, surgery and WBRT for solitary brain lesions without systemic disease, and SRS or WBRT followed by chemotherapy for palliative care. The overall prognosis is poor with a mean and median survival time from diagnosis of brain metastasis of 7 and 4.6 months, respectively. Conclusion: Future efforts through large prospective randomized trials are warranted to better describe the clinical presentation and identify more effective treatment plans.
Collapse
Affiliation(s)
- Kaleigh Fetcko
- Department of Neurosurgery, Indiana University, Indianapolis, Indiana, USA
| | - Dibson D Gondim
- Division of Neuropathology, Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA
| | - Jose M Bonnin
- Division of Neuropathology, Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA
| | - Mahua Dey
- Department of Neurosurgery, Indiana University, Indianapolis, Indiana, USA
| |
Collapse
|
308
|
Wang B, Huang Z, Gao R, Zeng Z, Yang W, Sun Y, Wei W, Wu Z, Yu L, Li Q, Zhang S, Li F, Liu G, Liu B, Leng L, Zhan W, Yu Y, Yang G, Zhou S. Expression of Long Noncoding RNA Urothelial Cancer Associated 1 Promotes Cisplatin Resistance in Cervical Cancer. Cancer Biother Radiopharm 2017; 32:101-110. [PMID: 28414550 DOI: 10.1089/cbr.2016.2156] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Affiliation(s)
- Bi Wang
- Department of Gynecology, Maternal and Child Health Hospital of Guiyang City, Guiyang, China
- School of Medical Laboratory Science, Guizhou Medical University, Guiyang, China
| | - Zhi Huang
- Department of Interventional Radiology, The Affiliated Baiyun Hospital of Guizhou Medical University, Guiyang, China
- Department of Interventional Radiology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China
| | - Rui Gao
- Guizhou Entry-exit Inspection and Quarantine Bureau, Guiyang, China
| | - Zhu Zeng
- School of Biology and Engineering, Guizhou Medical University, Guiyang, China
| | - Weiming Yang
- Department of Gynecology, Maternal and Child Health Hospital of Guiyang City, Guiyang, China
| | - Yuan Sun
- Department of Gynecology, Maternal and Child Health Hospital of Guiyang City, Guiyang, China
| | - Wei Wei
- Department of Gynecology, Maternal and Child Health Hospital of Guiyang City, Guiyang, China
| | - Zhongqing Wu
- Department of Gynecology, Maternal and Child Health Hospital of Guiyang City, Guiyang, China
| | - Lei Yu
- School of Medical Laboratory Science, Guizhou Medical University, Guiyang, China
| | - Qinshan Li
- School of Medical Laboratory Science, Guizhou Medical University, Guiyang, China
| | - Shuai Zhang
- Department of Interventional Radiology, The Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, China
| | - Fenghu Li
- Department of Interventional Radiology, The Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, China
| | - Guoli Liu
- Department of Interventional Radiology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China
| | - Bingjie Liu
- Department of Interventional Radiology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China
| | - Li Leng
- Department of Pediatrics, The Second Affiliated Hospital of Guiyang College of Traditional Chinese Medicine, Guiyang, China
| | - Wei Zhan
- Department of Pediatrics, The Second Affiliated Hospital of Guiyang College of Traditional Chinese Medicine, Guiyang, China
| | - Yanlong Yu
- Department of Interventional Radiology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China
| | - Guozhen Yang
- School of Medical Laboratory Science, Guizhou Medical University, Guiyang, China
| | - Shi Zhou
- Department of Interventional Radiology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China
- Department of Interventional Radiology, The Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, China
| |
Collapse
|
309
|
Barra F, Lorusso D, Leone Roberti Maggiore U, Ditto A, Bogani G, Raspagliesi F, Ferrero S. Investigational drugs for the treatment of cervical cancer. Expert Opin Investig Drugs 2017; 26:389-402. [DOI: 10.1080/13543784.2017.1302427] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- Fabio Barra
- Academic Unit of Obstetrics and Gynecology, IRCCS AOU San Martino – IST, Genoa, Italy
- Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy
| | - Domenica Lorusso
- Department of Gynecologic Oncology, IRCCS National Cancer Institute, Milan, Italy
| | - Umberto Leone Roberti Maggiore
- Academic Unit of Obstetrics and Gynecology, IRCCS AOU San Martino – IST, Genoa, Italy
- Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy
| | - Antonino Ditto
- Department of Gynecologic Oncology, IRCCS National Cancer Institute, Milan, Italy
| | - Giorgio Bogani
- Department of Gynecologic Oncology, IRCCS National Cancer Institute, Milan, Italy
| | | | - Simone Ferrero
- Academic Unit of Obstetrics and Gynecology, IRCCS AOU San Martino – IST, Genoa, Italy
- Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy
| |
Collapse
|
310
|
Xia J, Yu X, Song X, Li G, Mao X, Zhang Y. Inhibiting the cytoplasmic location of HMGB1 reverses cisplatin resistance in human cervical cancer cells. Mol Med Rep 2016; 15:488-494. [PMID: 27959427 DOI: 10.3892/mmr.2016.6003] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2015] [Accepted: 10/31/2016] [Indexed: 11/06/2022] Open
Abstract
Cervical cancer is the fourth most common malignancy in women worldwide, and resistance to chemotherapy drugs is the biggest obstacle in the treatment of cervical cancers. In the present study, the molecular mechanisms underlying cisplatin resistance in human cervical cancer cells were investigated. When human cervical cancer cells were treated with 10 µg/ml of cisplatin for 24 and 48 h, high mobility group box 1 (HMGB1) protein expression levels significantly increased in a time‑dependent manner. Comparisons between cisplatin‑sensitive HeLa cells and cisplatin‑resistant HeLa/DDP cells revealed higher levels of HMGB1 in HeLa/DDP cells than in HeLa cells. Additionally, the half maximal inhibitory concentration (IC50) value for cisplatin in HeLa/DDP cells was 5.3‑fold that in HeLa cells. Analysis of the distribution of cellular components revealed that HMGB1 translocation from the nucleus to cytoplasm contributed to cisplatin resistance. This was further confirmed by demonstration that ethyl pyruvate treatment suppressed the cytoplasmic translocation of HMGB1, resulting in inhibition of HeLa cell proliferation. Furthermore, endogenous HMGB1 was inhibited with HMGB1‑specific short hairpin (sh)RNA, and MTT assay results showed that interference with HMGB1 expression reduced cell viability and potentially reversed cisplatin resistance in HeLa cells. Transfection with HMGB1 shRNA was demonstrated to induce cell apoptosis in HeLa cells, as detected by FACS analysis. In addition, administration of recombinant HMGB1 protein in HeLa cells promoted cell autophagy, mediated by the phosphorylation of extracellular signal‑regulated kinase 1/2. Thus, cytoplasmic HMGB1 translocation and HMGB1‑induced cell autophagy are proposed to contribute to cisplatin resistance by inhibiting apoptosis of cervical cancer cells. HMGB1 could, therefore, represent a novel therapeutic target for, and a diagnostic marker of, chemotherapy resistant cervical cancers.
Collapse
Affiliation(s)
- Jiyi Xia
- School of Medical Information and Engineering, Southwest Medical University, Luzhou, Sichuan 646000, P.R. China
| | - Xiaolan Yu
- Department of Obstetrics and Gynecology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China
| | - Xueqin Song
- Experimental Medicine Center, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China
| | - Gang Li
- Department of Pediatrics, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China
| | - Xiguang Mao
- Department of Obstetrics and Gynecology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China
| | - Yujiao Zhang
- Department of Obstetrics and Gynecology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China
| |
Collapse
|
311
|
刘 健, 刘 静, 李 胜, 郑 迎, 郭 苏, 王 秀. [Inhibiting HSP70 expression enhances cisplatin sensitivity of cervical cancer cells]. NAN FANG YI KE DA XUE XUE BAO = JOURNAL OF SOUTHERN MEDICAL UNIVERSITY 2016; 37:475-481. [PMID: 28446399 PMCID: PMC6744087 DOI: 10.3969/j.issn.1673-4254.2017.04.09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 10/27/2016] [Indexed: 06/07/2023]
Abstract
OBJECTIVE To investigate the relationship between sensitivity to cisplatin (DDP) and the expression of HSP70 in cervical cancer cells in vitro. METHODS Cervical cancer Hela229 cells treated with different concentrations of DDP and the HSP70 inhibitor (PFT-µ) were examined for cell viability using MTT assay and colony forming ability. The cell apoptosis was analyzed by flow cytometry with propidium iodide staining and DAPI staining, and JC-1 staining was used to determine mitochondrial membrane potential. The expressions of HSP70, Bcl-2, Bax and caspase-3 were measured with Western blotting. A nude mouse model bearing Hela229 cell xenograft was used to evaluate the effect of DDP and PFT-µ on tumor growth. RESULTS Hela229 cells expressed a higher level of HSP70 than normal cervical cells. The combined use of PFT-µ significantly enhanced the inhibitory effect of DDP (P<0.01) and increased the cell apoptosis in Hela229 cells. JC-1 staining demonstrated that DDP combined with PFT-µ more obviously reduced mitochondrial membrane potential. DDP combined with PFT-µ more strongly lowered Bcl-2 expression and increased the expressions of casepase-3 and Bax than DDP alone. In the nude mouse model, PFT-µ significantly enhanced DDP sensitivity of Hela229 cell xenografts (P<0.01). CONCLUSIONS Inhibition of HSP70 expression can enhance the sensitivity of cervical cancer cell to DDP both in vivo and in vitro possibly by promoting cell apoptosis, suggesting the potential of HSP70 as a new target for gene therapy of cervical cancer.
Collapse
Affiliation(s)
- 健 刘
- 蚌埠医学院药学院,安徽 蚌埠 233000Bengbu Medical College, Bengbu 233030, China
- 蚌埠医学院第一附属医院妇瘤科,安徽 蚌埠 233004Department of Gynecological Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, China
| | - 静 刘
- 蚌埠医学院药学院,安徽 蚌埠 233000Bengbu Medical College, Bengbu 233030, China
- 蚌埠医学院第一附属医院妇瘤科,安徽 蚌埠 233004Department of Gynecological Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, China
| | - 胜泽 李
- 蚌埠医学院药学院,安徽 蚌埠 233000Bengbu Medical College, Bengbu 233030, China
- 蚌埠医学院第一附属医院妇瘤科,安徽 蚌埠 233004Department of Gynecological Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, China
| | - 迎奥 郑
- 蚌埠医学院药学院,安徽 蚌埠 233000Bengbu Medical College, Bengbu 233030, China
- 蚌埠医学院第一附属医院妇瘤科,安徽 蚌埠 233004Department of Gynecological Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, China
| | - 苏阳 郭
- 蚌埠医学院药学院,安徽 蚌埠 233000Bengbu Medical College, Bengbu 233030, China
- 蚌埠医学院第一附属医院妇瘤科,安徽 蚌埠 233004Department of Gynecological Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, China
| | - 秀 王
- 蚌埠医学院药学院,安徽 蚌埠 233000Bengbu Medical College, Bengbu 233030, China
| |
Collapse
|
312
|
刘 健, 刘 静, 李 胜, 郑 迎, 郭 苏, 王 秀. [Inhibiting HSP70 expression enhances cisplatin sensitivity of cervical cancer cells]. NAN FANG YI KE DA XUE XUE BAO = JOURNAL OF SOUTHERN MEDICAL UNIVERSITY 2016; 37:475-481. [PMID: 28446399 PMCID: PMC6744087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 10/27/2016] [Indexed: 07/30/2024]
Abstract
OBJECTIVE To investigate the relationship between sensitivity to cisplatin (DDP) and the expression of HSP70 in cervical cancer cells in vitro. METHODS Cervical cancer Hela229 cells treated with different concentrations of DDP and the HSP70 inhibitor (PFT-µ) were examined for cell viability using MTT assay and colony forming ability. The cell apoptosis was analyzed by flow cytometry with propidium iodide staining and DAPI staining, and JC-1 staining was used to determine mitochondrial membrane potential. The expressions of HSP70, Bcl-2, Bax and caspase-3 were measured with Western blotting. A nude mouse model bearing Hela229 cell xenograft was used to evaluate the effect of DDP and PFT-µ on tumor growth. RESULTS Hela229 cells expressed a higher level of HSP70 than normal cervical cells. The combined use of PFT-µ significantly enhanced the inhibitory effect of DDP (P<0.01) and increased the cell apoptosis in Hela229 cells. JC-1 staining demonstrated that DDP combined with PFT-µ more obviously reduced mitochondrial membrane potential. DDP combined with PFT-µ more strongly lowered Bcl-2 expression and increased the expressions of casepase-3 and Bax than DDP alone. In the nude mouse model, PFT-µ significantly enhanced DDP sensitivity of Hela229 cell xenografts (P<0.01). CONCLUSIONS Inhibition of HSP70 expression can enhance the sensitivity of cervical cancer cell to DDP both in vivo and in vitro possibly by promoting cell apoptosis, suggesting the potential of HSP70 as a new target for gene therapy of cervical cancer.
Collapse
Affiliation(s)
- 健 刘
- 蚌埠医学院药学院,安徽 蚌埠 233000Bengbu Medical College, Bengbu 233030, China
- 蚌埠医学院第一附属医院妇瘤科,安徽 蚌埠 233004Department of Gynecological Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, China
| | - 静 刘
- 蚌埠医学院药学院,安徽 蚌埠 233000Bengbu Medical College, Bengbu 233030, China
- 蚌埠医学院第一附属医院妇瘤科,安徽 蚌埠 233004Department of Gynecological Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, China
| | - 胜泽 李
- 蚌埠医学院药学院,安徽 蚌埠 233000Bengbu Medical College, Bengbu 233030, China
- 蚌埠医学院第一附属医院妇瘤科,安徽 蚌埠 233004Department of Gynecological Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, China
| | - 迎奥 郑
- 蚌埠医学院药学院,安徽 蚌埠 233000Bengbu Medical College, Bengbu 233030, China
- 蚌埠医学院第一附属医院妇瘤科,安徽 蚌埠 233004Department of Gynecological Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, China
| | - 苏阳 郭
- 蚌埠医学院药学院,安徽 蚌埠 233000Bengbu Medical College, Bengbu 233030, China
- 蚌埠医学院第一附属医院妇瘤科,安徽 蚌埠 233004Department of Gynecological Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, China
| | - 秀 王
- 蚌埠医学院药学院,安徽 蚌埠 233000Bengbu Medical College, Bengbu 233030, China
| |
Collapse
|
313
|
Janetschek G, Weitzel D, Stein W, Müntefering H, Alken P. Prenatal diagnosis of neuroblastoma by sonography. Urology 1984; 38:93. [PMID: 30791957 PMCID: PMC6385443 DOI: 10.1186/s13046-019-1109-z] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2018] [Accepted: 02/15/2019] [Indexed: 12/24/2022]
Abstract
Background Zoledronic acid is the most potent osteoclast inhibitor and is widely used for advanced cancer patients with bone metastasis, but its role on cancer stem cells (CSCs) remains unclear. In the present study, we aimed to identify the stemness phenotypic characteristics of CSCs derived from cervical cancer cells and explore the anti-cancer efficiency of zoledronic acid on these cells, as well as the possible molecular mechanisms. Methods Stemness phenotypic identification of cervical cancer cells derived CSCs was performed via sphere formation efficiency (SFE), tumorigenesis, immunofluorescence staining, Transwell assay, and western blot. Anti-cancer efficiency of zoledronic acid on these cells (including proliferation, stemness phenotype, apoptosis, and cell cycle) was carried out through MTT assay, SFE, transwell, DAPI staining, flow cytometry, immunofluorescence, TUNEL staining, and western blot, both in vitro and in vivo. Results Enhanced self-renewal ability, including SFE and tumorigenesis, was verified in cervical cancer cells derived CSCs compared to parental cervical cancer cells. Specifically, the expression of ALDH1, Sox2, CD49f, Nanog, and Oct4 was significantly up-regulated in cervical cancer cells derived CSCs. Furthermore, enhanced migratory ability was observed in these cells along with up-regulated N-cadherin and Vimentin and down-regulated E-cadherin. Zoledronic acid inhibited cervical cancer cells derived CSCs proliferation in vitro and in vivo. The stemness phenotype of these CSCs including tumor sphere formation, migration, as well as the expression of the aforementioned associated markers was also suppressed. In addition, zoledronic acid significantly induced apoptosis and cell cycle arrest of cervical cancer cells derived CSCs in a dose-dependent manner. Mechanistically, the expression of phosphorylated Erk1/2 and Akt was significantly increased in cervical cancer cells derived CSCs compared to parental cervical cancer cells. Zoledronic acid inhibited phosphorylated Erk1/2 and Akt in cervical cancer cells derived CSCs. IGF-1, a potent stimulator for Erk1/2 and PI3K/Akt, attenuated the aforementioned anti-cancer effect of zoledronic acid. Conclusions Zoledronic acid inhibited the growth of cervical cancer cells derived CSCs through attenuating their stemness phenotype, inducing apoptosis, and arresting cell cycle. The suppression of phosphorylated Erk1/2 and Akt was involved in this process. Electronic supplementary material The online version of this article (10.1186/s13046-019-1109-z) contains supplementary material, which is available to authorized users.
Collapse
|